Gold is hot its the talk of the town, it will remain a volatile issue with huge gains and losses going into 2010. Half of the investors think its toped out and will head to $600 and flat line; while the other half see $1300 in their sights and $2000 over the next year..whos right?

Well I am in deep in gold and now haver been watching the little junior bio-techs develope H1N1 and Aids fighting medicine. As well the one little company that has developed a new pain killer from snake venom...yes it has been approved for sale in the USA and is currently going forward with an agressive marketing plan. Imagine and compound and spray that quickly kills pain from headaches or even muscle ache. This is a multi bllion dollar industry with products just barely having an effect on pain.

This is the start of a new generation in thinking and you will see this company head to a target of $10.00USD in the next 12 months. Most sites would charge you for this insight and research but I am going to let you have it for nothing. The choice is your but I know a majority of you will only look at this in the news a year from now and say..wow I remember when that was 46 cents a share.

A biotechnologycompany that isdeveloping treatments for Adrenomyeloneuropathy (AMN),HIV and MultipleSclerosis (MS), has announced today that its recentlylaunched painreliever, Cobroxin, was selected as the "Best New Product"at theEfficient Collaborative Retail Marketing (ECRM) Conference.Cobroxinwas chosen as the award recipient by conference attendees,includingseveral of the leading national retailers.

Nutra Pharma Corp. (OTCBB: NPHC),

"Winningthis awardis an exciting achievement for Nutra Pharma, as it reflectsthesignificant amount of positive response we have received fromretailerswho are looking to offer their customers a safe andeffectivealternative to current pain relievers," commented Rik J.Deitsch,Chairman and CEO of Nutra Pharma. "As we begin introducingCobroxinthrough retailers this fall, we plan to continue our effortseducatingboth retailers and consumers about Cobroxin's uniqueanalgesicproperties, which do not rely on opiates or acetaminophen forits painrelieving effects," he concluded.

Cobroxin is the firstOTCpain reliever clinically proven to treat Stage 2 (moderate tosevere)chronic pain. The drug, which was developed by NutraPharma'swholly-owned drug discovery subsidiary, ReceptoPharm, will beavailableas an oral spray (NDC47219-102-52) for treating lower backpain,migraines, neck aches, shoulder pain, cramps and neuralgia and asatopical gel (NDC47219-104-50) for treating repetitivestress,arthritis, and joint pain.

Additional benefits to Cobroxin include:

-- All Natural

-- Non-Addictive

-- Non-Narcotic

-- Non-Opiate

-- More Potent than Morphine

-- Long Lasting

Recently,NutraPharma announced a licensing agreement that grants XenaCareHoldings(OTCBB: XCHO) ongoing exclusive marketing and distributionrights forCobroxin within the United States in return for meetingspecific minimumperformance requirements. In addition, the Companyalso announcedsuccessful submission of final Cobroxin packaging andlabeling to theFood and Drug Administration (FDA), the final steprequired to beginselling Cobroxin.